Skip to main content

Table 1 Baseline characteristics of the study sample

From: Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases – a claims data analysis

Study sample
N 36,817 %
 Idiopathic interstitial pneumonias (IIP) 14,453 39.3
 Other fibrosing ILDs (OFI) 7187 19.5
 Sarcoidosis (SARC) 9106 24.7
 Drug-associated ILDs (DAI) 407 1.1
 Pneumoconiosis (PNE) 1579 4.3
 Radiation-associated pneumonitis (RAP) 464 1.3
 Eosinophilic pneumonia (EPP) 1518 4.1
 Hypersensitivity pneumonitis (HP) 967 2.6
 Connective tissue disease-associated ILD (CTD) 1140 3.1
Ø age (years) at diagnosis (SD) 66.0 14.6
Male gender 20,704 56.2
Ø survival in months (SD) 29.6 0.31
Dead at end of observation period 11,422 31.0
Median number of comorbidities (IQR)a 5.0 [3.7]
Non-ILD-related hospitalization (%) during observation 24,665 67.0
ILD-related hospitalization (%) during observation 3304 9.0
  1. All figures as N (%) unless reported otherwise
  2. IQR, interquartile range, SD standard deviation
  3. a31 comorbid conditions from the Elixhauser Index amended by PH, lung cancer, GERD, IHD, thrombosis, and OSAS yields a maximum of 37